Patients Taking Cymbalta reg; Reported Reduced Pain Severity Of Osteoarthritis Of The Knee In New Study
New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment that lasted throughout the 13-week trial.
Actemra Is First Biologic Agent To Show Better Efficacy Than Methotrexate In RA
PARIS: The interleukin-6 receptor inhibitor Actemra (tocilizumab) achieves significantly greater reduction in the signs and symptoms of rheumatoid arthritis (RA) than the current standard of care, methotrexate, according to two international clinical trials reported this week at EULAR 2008, the Annual European Congress of Rheumatology.
Joint Damage Is Inhibited With Enbrel reg; Etanercept Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis
Data presented recently show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a change in TSS^a
Cimzia reg; Is The First Anti-TNF Shown To Inhibit Progression Of Joint Damage As Early As 16 Weeks In Rheumatoid Arthritis
UCB has announced new data showing that Cimzia (certolizumab pegol), the only PEGylated, Fc-Free anti-TNF (Tumor Necrosis Factor), combined with methotrexate (MTX), significantly inhibits progression of joint damage in patients with active rheumatoid arthritis (RA) as early as 16 weeks after the start of treatment.
Novel DNA Microarray Chip Predicts Functional Impairment And Remission In Rheumatoid Arthritis
A new DNA microarray chip can predict severe disability and remission in patients with rheumatoid arthritis (RA), as presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. The chip (called the 'ARTchip') has yielded two clinical-genetic models of RA outcomes, to assist physicians in anticipating likely disease progression and prognosis and thereby guide decisions on the best course of treatment for individual patients.
Oily Fish Can Protect Against RA, But Smoking And Psychosocial Stress Increase Its Risk
Results from the EIRA studyNew data presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that intake of oily fish is associated with a reduced risk of developing rheumatoid arthritis (RA), whereas psychosocial work stress and smoking can increase the risk of developing the condition.
Specific Mutations In The IL2RA Gene Associated With Juvenile Idiopathic Arthritis
Certain single nucleotide polymorphisms (SNPs) within the interleukin 2 receptor alpha (IL2RA) gene region are shown to be associated with juvenile idiopathic arthritis (JIA), according to a new study of two independent cohorts presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Rheumatoid Arthritis Is A Risk Factor For Cardiovascular Disease
The risk of cardiovascular disease (CVD) for people with rheumatoid arthritis (RA) has been found to be comparable to the risk of CVD in people with type 2 diabetes, according to the conclusions of two studies presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
In Risk Of Severe Cardiovascular Events, Rheumatoid Arthritis Factors Equal To Cardiovascular Factors
Certain cardiovascular disease (CVD) risk factors and rheumatoid arthritis (RA) disease factors have a similar effect on an RA patient's risk of experiencing myocardial infarction (MI) or stroke, according to a new study presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Recommendations For Rheumatoid Arthritis Therapy Presented By American College Of Rheumatology
To manage the painful and incapacitating symptoms of rheumatoid arthritis (RA), a chronic, inflammatory joint disease, the majority of patients rely on disease-modifying antirheumatic drugs (DMARDs). In addition to trusted nonbiologic DMARDs, a number of biologic agents now promise to improve treatment for RA.